Share Name Share Symbol Market Type Share ISIN Share Description
Ixico LSE:IXI London Ordinary Share GB00BCLY7L40 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 29.50p 29.00p 30.00p 29.50p 29.50p 29.50p 4,370 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 4.1 -1.9 -5.7 - 13.80

Ixico Share Discussion Threads

Showing 151 to 175 of 175 messages
Chat Pages: 7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
17/9/2018
10:03
I wish companies would be honest and not treat shareholders like idiots. Ixico is currently planning a Capital Reorganisation where every 100 shares will be consolidated and then subdivided to remove 75% of the shareholder base. This will save 'significant costs and a considerable administrative burden to the Company.' Will it? It costs about £10 per shareholder per annum once you are beyond 750 shareholders in terms of registrar and annual report costs. A more pressing need to reorganise is the chaos that currently prevails from having Phytopharm 50p share, Ixico 50p share and Ixico 1p share certificates all currently in existence and all equally valid. Why not clarify this in the circular to shareholders?
danny baker
11/9/2018
12:24
Sbtx is one to look!Human Trials Starting Soon (this month)!Possible Big rerate!!
costax1654x
11/9/2018
08:45
Presumably Roche?
toffeeman
11/9/2018
08:12
good start
curlly
11/9/2018
07:51
That's 2.3m per year for the next 4 years sounds good to me
curlly
11/9/2018
07:22
IXICO plc Contract with top 10 global pharmaceutical companySource: UK Regulatory (RNS & others)TIDMIXIRNS Number : 3166AIXICO plc11 September 201811 September 2018IXICO plc("IXICO" or the "Company")Significant new contract with a top 10 global pharmaceutical company to provide specialist medical imaging services for a Phase III Huntington's disease clinical trialHighlights the value of IXICO's data science expertise in neuroscience drug development.IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed a new contract with a top 10 global pharmaceutical company, to provide its technology enabled imaging services in support of a Pivotal Phase III study in Huntington's disease. The contract value of GBP9.1m will be delivered over a four year term.As part of this study, IXICO will utilise its expertise to optimise, standardise and collect magnetic resonance imaging (MRI) data from specialist imaging centres across North America, Latin America, Europe, Asia and Australasia. IXICO's data science expertise and artificial intelligence (AI) software algorithms will be applied to provide insights into brain cellular microstructure and neuronal connectivity to support the evaluation of drug safety and efficacy.This contract expands IXICO's relationship with an existing client and is the fourth new contract in Huntington's disease announced this financial year. It demonstrates the increasing adoption of IXICO's scientific and operational expertise in this important area of clinical development; Huntington's disease is a rare genetic neurodegenerative disorder which affects movement, cognition and behaviour.Giulio Cerroni, CEO of IXICO, said: "I am delighted to announce this new contract for a Pivotal Phase III clinical trial with an existing client which demonstrates confidence in IXICO's services to deliver valuable insights through our proprietary data analytics platform. Huntington's disease is an area of significant unmet medical need as there are currently no effective marketed treatments. This latest contract award reflects our experience working in this important area of neuroscience drug development which, together with previously announced new contracts and contract extensions, provides a strong foundation for future growth."For further information please contact: IXICO plc Giulio Cerroni, Chief Executive Officer Tel: +44 20 3763 7499 Susan Lowther, Chief Financial Officer Shore Capital (Nomad and Broker) Tel: +44 20 7408 4090 Edward Mansfield / Anita Ghanekar / Daniel Bush FTI Consulting Limited (Investor Relations) Tel: +44 20 3727 1000 Simon Conway/Mo Noonan About IXICOIXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our clients' neurodegenerative therapeutic pipeline through the application of advanced medical imaging and digital health technologies.IXICO's specialist data analytics services are used by the global pharmaceutical industry to analyse brain scan data and digital biomarkers to measure disease status and progression, enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical trial process evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDCNTEALNEFAAPEFF(END) Dow Jones NewswiresSeptember 11, 2018 02:00 ET (06:00 GMT)
jpuff
31/8/2018
14:45
Topped up here
jpuff
31/8/2018
14:27
Wow 26% drop - why?
jpuff
31/8/2018
13:47
Over-reaction on light selling...ridiculous
molatovkid
23/8/2018
20:55
Hi Jpuff, Ihave held Ixico since they were listed and have a decent holding, I agree that patience is required but thinkthat the next year could be transformational. If you have a look at the Proactive investors website there was a very good article yesterday and also a video, well worth a look.
thelagerkhan
23/8/2018
19:47
Such a frustrating share this one. Just when you think it's going to move ahead it always pulls back again! Things look rosy though so not sure why this tight range persists. Guess I'll just be more patient but I'm getting old now lol
jpuff
30/5/2018
16:36
Another good flurry of buying activity today. Holding a few myself but not a large holding. They are quite illiquid so can move either way quickly once noticed. Fingers crossed for a break out northwards one day soon.
jpuff
23/5/2018
17:18
Some decent chunky buying activity today. Hope it can break out of this long range bound area soon.
jpuff
30/1/2018
09:26
Could share price weakness be due to the fact that furthest out broker forecasts for fy 2019 show as still loss making and with a total forecast loss of 12.5p per share (adjusted eps 2017-2019 inclusive) Lots of room for variations either up or down so (imo) highish risk unless you have a lot of patient years to wait (e&oe etc Cautions etc)
pugugly
30/1/2018
07:49
The Company is moving in the right direction, good growth in sales, unfortunately the share price is not joining in.
chrisgail
18/12/2017
10:43
Very quiet share this one. I own but I'm not sure why ;). Hopefully one day Rodney....
jpuff
28/7/2017
15:51
This is an 'active' day for IXICO, whats going on?
chrisgail
21/5/2017
07:24
You can put the charts in , IXICO has been trading for years prior to the reverse takeover Long term charts show it has BOMBED or TANKED , whichever term you like But perhaps they have been left out for a reason
buywell3
13/4/2017
13:26
Tightly held I think. Very little buying moves the price.
geoff80
13/3/2017
09:27
Strange that the buys are showing on here as sells this morning? Somebody trying to manipulate something ?
jondev
07/3/2017
15:01
God this share is a dog!
jpuff
07/3/2017
13:29
Geoff80, can you edit the header and put in some charts tks!
ny boy
07/3/2017
13:23
Any idea why the sudden drop?
jondev
20/12/2016
10:15
Not many shares about so little buying or selling has a marked effect.
geoff80
20/12/2016
09:16
Has the share price gone down because they spent 2.7 million buying some random company with no consultation from shareholders???
jondev
Chat Pages: 7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180920 13:30:20